Curepharma
ActiveSummary
Curepharma has been active since 1983 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €355,161 and a net result of -€63,131. Equity is growing by about 5.2% per year across the filed financial years. Its solvency ranks better than 81% of 12,737 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 18 days late
2025
31-12
Financial
Weakest financial yearnet -€63,131
Net result drops to -€63,131, the lowest in the series.
31-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
27-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 27 days late
03-01
Gazette deed
Appointment: SARAVI (director)Permanent representative: MALEKZADEH SARAVI Mahsa · Capital conversion · Name change11 facts ▸
Gazette deed
Appointment: SARAVI (director)
Permanent representative: MALEKZADEH SARAVI Mahsa · Capital conversion · Name change11 facts ▸
- General meeting, 13-12-2023
- Other provision, “aanpassing statuten aan WVV met behoud rechtsvorm, statuten aanpassen aan Wetboek van Vennootschappen en Verenigingen en rechtsvorm besloten vennootschap(afgeko…” (deed in Dutch)
- Capital conversion, “van rechtswege omzetting, artikel 39,§2,tweede lid,wet van 2019-03-23” (deed in Dutch)
- Capital conversion, “vormen en meerderheden van statutenwijziging, volledige opheffing statutair onbeschikbare eigen vermogensrekening en beschikbaar maken voor uitkering” (deed in Dutch)
- Name change, Curepharma
- Amendment of the articles
- Registered office clause, “2020 Antwerpen,Camille Huysmanslaan 95, bevestiging adres zetel” (deed in Dutch)
- Power of attorney, Jan VAN ERMENGEM
- Director appointment, SARAVI (director (not named in the articles))
- Permanent representative, MALEKZADEH SARAVI Mahsa
- Permanent representative, MALEKZADEH SARAVI Mahsa (vaste vertegenwoordiger van de vennootschap bij mandaat in andere vennootschap als bestuurder,vereffenaar)
2023
29-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 29 days late
2022
25-10
Gazette deed
Resignations: Marleen Masui (director) and Olivier Vangrunderbeek (director)Appointment: Saravi BV (director) · Permanent representative: Mahsa Malekzadeh · Director discharge8 facts ▸
Gazette deed
Resignations: Marleen Masui (director) and Olivier Vangrunderbeek (director)
Appointment: Saravi BV (director) · Permanent representative: Mahsa Malekzadeh · Director discharge8 facts ▸
- General meeting, 01-10-2022
- Director resignation, Marleen Masui (director)
- Director resignation, Olivier Vangrunderbeek (director)
- Director discharge, Marleen Masui
- Director discharge, Olivier Vangrunderbeek
- Other provision, “goedkeuring vergoedingen bestuurders”, 2022 (deed in Dutch)
- Director appointment, Saravi BV (director (not named in the articles))
- Permanent representative, Mahsa Malekzadeh
02-06
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
04-06
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
31-12
Financial
Highest result from 2018 to 2025net €95,408 ▲65.8%
Operating result €123,234, net result €95,408, both a record.
23-06
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
28-05
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
04-06
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
24-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 42 annual accounts filed, the latest 10 are here; all 42 are under Financials.
2 of 4 deeds read
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.